第三條 審計委員會成員須全部由非執行董事組成，審計委員會人數至少三 名，獨立非執行董事應佔多數，委員中至少有一名為符合《香港上市規則》的具備 合適專業資格或會計或相關財務管理專長之獨立非執行董事。 第四條 審計委員會委員由董事長、三分之一以上董事會成員或董事會提名 委員會提名，並由董事會以全體董事過半數選舉產生。審計委員會全部成員均須 具有能夠勝任審計委員會工作職責的專業知識和商業經驗。 第五條 審計委員會設審計委員會主席（召集人）一名，並須為獨立非執行董 事，負責主持審計委員會工作；審計委員會主席須由董事會在審計委員會委員內 選舉產生。 第六條 現時負責審計公司賬目的會計師事務所的前合夥人在以下日期（以 日期較後者為準）起計兩年內，不得擔任審計委員會的委員： （一） 其終止成為該會計師事務所合夥人的日期；或 廣州銀諾醫藥集團股份有限公司 董事會審計委員會工作細則 第一章 總則 第一條 為強化董事會決策功能，持續完善廣州銀諾醫藥集團股份有限公司 （以下簡稱「公司」，及其附屬公司以下簡稱「集團」）內控體系建設，確保董事會 對經理層的有效監督管理，不斷完善公司治理結構，根據《中華人民共和國公司 法》（以下簡稱「《 ...

廣州銀諾醫藥集團股份有限公司 董事會薪酬與考核委員會工作細則 第一章 總則 第一條 為進一步建立健全廣州銀諾醫藥集團股份有限公司（以下簡稱「公 司」）薪酬與考核管理制度，完善公司治理結構，根據《中華人民共和國公司法》 （以下簡稱「《公司法》」）、《香港聯合交易所有限公司證券上市規則》（以下簡稱 「《香港上市規則》」）等相關適用法律、行政法規、部門規章、規範性文件及《廣州 銀諾醫藥集團股份有限公司章程》（以下簡稱「《公司章程》」），依照董事會決議， 公司特設立董事會薪酬與考核委員會，並結合公司實際，制定本《董事會薪酬與 考核委員會工作細則》（以下簡稱「本細則」）。 第二條 薪酬與考核委員會是公司董事會下設的專門工作機構，主要負責研 究制定董事、監事與高級管理人員的考核標準並按照標準進行考核，提出意見和 建議；負責研究制定、審查公司董事、監事和高級管理人員的薪酬計劃或方案。 第三條 本細則所稱董事是指公司的董事，高級管理人員是指公司的總經 理、財務負責人（首席財務官）、董事會秘書、《公司章程》規定的其他高級管理人 員以及由董事會明確聘任為公司高級管理人員的其他人員。 第四條 薪酬與考核委員會大多數成員應為獨立非執 ...

廣州銀諾醫藥集團股份有限公司 章程 （H股發行後適用） 1 | 第一章 | 總則 | 4 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 5 | | 第三章 | 股份 | 6 | | 第一節 | 股份發行 | 6 | | 第二節 | 股份增減和回購 | 10 | | 第三節 | 股份轉讓 | 11 | | 第四章 | 股東和股東會 | 12 | | 第一節 | 股東 | 12 | | 第二節 | 股東會的一般規定 | 18 | | 第三節 | 股東會的召集 | 21 | | 第四節 | 股東會的提案與通知 | 23 | | 第五節 | 股東會的召開 | 25 | | 第六節 | 股東會的表決和決議 | 29 | | 第五章 | 董事會 | 34 | | 第一節 | 董事 | 34 | | 第二節 | 董事會 | 38 | | 第六章 | 總經理及其他高級管理人員 | 43 | | 第七章 | 監事會 | 45 | | --- | --- | --- | | 第一節 | 監事 | 45 | | 第二節 | 監事會 | 45 | | 第八章 | 財務會計制度、利潤分配和審計 | 4 ...

Group 1 - The core viewpoint of the news is that Silverno Pharmaceuticals-B (2591.HK) has seen significant interest in its public offering, achieving an oversubscription rate of approximately 5,364 times, making it the second highest oversubscription this year after Mixue Group (2097.HK) [1] - The total subscription amount for Silverno Pharmaceuticals reached around HKD 370 billion, attracting approximately 260,000 investors [1] - The offering price for Silverno Pharmaceuticals was set at HKD 18.68, with a total fundraising target of HKD 683 million, and the stock is expected to be listed on Friday, August 15 [1]

Group 1: Company Filings - Three companies submitted applications to the Hong Kong Stock Exchange (HKEX) from August 4 to August 10, with one company passing the hearing [1] - Fujian Haixi New Drug Creation Co., Ltd. (Haixi New Drug) is a pharmaceutical company with a diverse product portfolio and pipeline, having received approvals for 14 generic drugs and four innovative drugs in development. Revenue for 2022 to 2025 is projected to be approximately RMB 2.12 billion, RMB 3.17 billion, RMB 4.67 billion, and RMB 2.49 billion respectively [2] - Shenzhen Haiqing Zhiyuan Technology Co., Ltd. (Haiqing Zhiyuan) specializes in multispectral AI technology, holding a 3.5% market share in the Chinese multispectral AI industry, ranking first. Revenue for 2022 to 2025 is projected to be approximately RMB 2.25 billion, RMB 1.17 billion, RMB 5.23 billion, and RMB 824.2 million respectively [3] - Ningbo Joyson Electronic Corp. (Joyson Electronics) is a provider of smart automotive technology solutions, ranking as the second-largest supplier of passive safety products in China and globally. Revenue for 2022 to 2025 is projected to be approximately RMB 49.793 billion, RMB 55.728 billion, RMB 55.864 billion, and RMB 19.709 billion respectively [4] Group 2: Company Hearings and Listings - Shuangdeng Group Co., Ltd. (Shuangdeng) passed the listing hearing on August 10, focusing on energy storage solutions for the big data and communications sectors. Revenue for 2022 to 2025 is projected to be approximately RMB 4.072 billion, RMB 4.260 billion, RMB 4.499 billion, and RMB 1.867 billion respectively [5][6] - Two companies are in the process of going public: Yinnuo Pharmaceutical-B (02591.HK) plans to offer 36.56 million H-shares at HKD 18.68 per share, while Zhonghui Biotechnology-B (02627.HK) plans to offer 33.44 million H-shares at HKD 12.90 per share, with the latter seeing a subscription rate of 4,007.64 times [7] - Dongyang Sunshine Pharmaceutical (HK:06887) was listed on August 7, 2025, closing at HKD 59.90, reflecting a 4.17% increase [8] Group 3: Market Trends and Regulations - The Hong Kong IPO market has raised nearly HKD 130 billion this year, with new regulations effective from August 4 aimed at optimizing pricing and allocation mechanisms for IPOs [9] - As of July 25, 2025, 52 companies have listed on the Hong Kong Stock Exchange, nearing the total of 75 for the previous two years combined. A notable trend is the increasing number of A-share companies seeking to list in Hong Kong [10] - The Hong Kong Stock Exchange aims to enhance the robustness of new stock pricing and allocation mechanisms to meet the needs of various local and international investors [11]

Group 1 - The core viewpoint of the article is that Silver Noble Pharmaceuticals-B (02591) is currently in the process of an IPO, attracting significant interest from investors [1] - As of August 8, a total of HKD 39.30325 billion has been lent to Silver Noble Pharmaceuticals by brokers including Futu, Huatai, and others [1] - The IPO has been oversubscribed by more than 576 times, indicating strong demand for the shares [1]

Major Events - Silver诺医药-B (02591) is set to conduct an IPO from August 7 to August 12, with an expected listing date of August 15 [1] - Boan Biotech (06955) plans to place 48 million shares at a discount of approximately 8.78%, aiming to raise about HKD 780 million [1] - Derin Holdings (01709) intends to raise HKD 653.3 million, focusing on the development of blockchain, RWA, and virtual asset businesses [1] - Fuhong Hanlin (02696) received FDA approval to initiate a Phase 1 clinical trial for HLX43, a PD-L1 targeted antibody-drug conjugate for thymic cancer treatment [1] - China Biopharmaceutical (01177) obtained NMPA approval for the Phase II clinical trial application of LM-24C5, a dual antibody targeting CEACAM5/4-1BB [1] Financial Reports - China Mobile (00941) reported a shareholder profit of HKD 84.235 billion, a year-on-year increase of 5.03% [1] - Manulife Financial-S (00945) announced a core profit of CAD 1.7 billion for the second quarter [1] - Swire Properties (01972) reported a basic profit attributable to shareholders of HKD 4.42 billion, a year-on-year growth of 15% [1] - Hutchison Whampoa (00013) posted a net profit of USD 455 million, a significant year-on-year increase of 1663.32% [1] - MGM China (02282) disclosed a net profit of HKD 2.383 billion, a year-on-year decrease of 11.25% [1] - SMIC (00981) reported a shareholder profit of USD 132 million for the second quarter, with a revenue guidance for the third quarter indicating a sequential growth of 5% to 7% [1] - Zai Lab (09688) achieved a total revenue of approximately USD 216 million for the first half of the year, reflecting a year-on-year growth of 15.35% [1] - Innovent Biologics (01801) reported total product revenue exceeding RMB 5.2 billion for the first half of the year, maintaining a strong growth rate of over 35% [1] - Pacific Basin Shipping (02343) announced a profit attributable to shareholders of USD 25.6 million, a year-on-year decrease of 56% [1] - Lee & Man Paper Manufacturing (02314) reported a net profit of HKD 811 million, a year-on-year increase of 0.7%, with an interim dividend of HKD 0.066 per share [1] - Swire Group reported a profit attributable to shareholders of HKD 815 million for the first half of the year, a year-on-year decrease of 79% [1] - Lee & Man Chemical Company (00746) reported a profit increase of 36.0% to HKD 327 million, with an interim dividend of HKD 0.195 per share [1] - Hua Hong Semiconductor (01347) reported a profit attributable to parent company owners of USD 7.952 million for the second quarter, a year-on-year increase of 19.2% [1] - Wharf Real Estate Investment (01997) reported a loss attributable to shareholders of HKD 2.406 billion, a year-on-year increase of 128.71%, with the first interim dividend of HKD 0.066 per share [1] - Dekang Agriculture (02419) issued a profit warning, expecting a year-on-year increase in fair value adjustments of biological assets to approximately RMB 1.1 billion to 1.4 billion [1] - Mongol Mining (00975) issued a profit warning, anticipating a net loss of approximately USD 15 million to 25 million for the first half of the year, marking a shift from profit to loss [1] - Dongfeng Motor Group (00489) issued a profit warning, expecting a decline in net profit attributable to the parent company of 90% to 95% for the first half of the year [1]

银诺医药-B(02591)正在招股中。截止8月7日，富途、辉立、耀才等券商合计为银诺医药借出63.0504亿 港元，超购逾91倍。 本文源自智通财经网 ...

Investment Rating - The report suggests a cautious subscription for the company [2]. Core Insights - The company focuses on the research and commercialization of drugs for diabetes (T2D) and obesity, with its core product being Isuparaglutide α, which received NMPA approval in January 2025 and was launched in China in February 2025 [2][4]. - The company has a comprehensive pipeline targeting metabolic diseases, including other candidates like YN202, YN203, and YN209 [2]. - The global obesity/overweight drug market is projected to grow to USD 36.9 billion from 2024 to 2028, with a CAGR of 21.5%, while the Chinese market is expected to reach RMB 12.2 billion with a CAGR of 30.6% during the same period [3]. - The company reported revenue of RMB 38.1 million for the five months ending May 31, 2025, with a gross margin of 89.3% [4]. Summary by Sections IPO Details - The company plans to raise HKD 610 million through its IPO, with a share price of HKD 18.68 and a total offering of 3,655,000 shares [1]. Financial Performance - The company recorded a net loss of RMB 175 million in 2024, indicating it is still in a loss-making phase despite being in a rapidly growing market [4]. Market Potential - The Chinese GLP-1 receptor agonist market is expected to grow from RMB 400 million to RMB 9.5 billion from 2024 to 2028, with a CAGR of 123.3% [3].

| | 新股好展 (8月7日) | | | | --- | --- | --- | --- | | 新股 | 券商 | 子展(亿港元) | 息率(%) | | 银诺医药- | 富途 | 37.23 | 0.00 | | | 辉立 | 7.00 | 0.00 | | | 耀才 | 3.00 | 0.00 | | | 信诚 | 2.00 | 0.00 | | | 化成 | 0.80 - | 0.00 | | B(02591) | 容立 | 0.5843 | 0.00 | | | 其他总和 | 12.4361 | | | | 并计 | 63.0504 | | | | | 集资额:0.68亿港元 | | | | | 认购: 超额逾91倍 | | 智通财经APP获悉，银诺医药-B(02591)正在招股中。截止8月7日，富途、辉立、耀才等券商合计为银诺医药借出63.0504亿港元，超购逾91 倍。 ...